C12N 2710/14034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/14034 (Use of virus or viral component as vaccine) appears on 9 US grants and 17 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 17
- Assignees
- 14
- Inventors
- 39
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 3 |
| 2021 | 0 | 1 |
| 2022 | 2 | 2 |
| 2023 | 1 | 0 |
| 2024 | 3 | 4 |
| 2025 | 0 | 2 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method of producing an immunogenic composition7 Jul 2026US 12,673,094 B2Boehringer Ingelheim Animal Health USA Inc.
- Universal influenza vaccine1 Oct 2024US 12,102,674 B2Cambridge Technologies, Inc.
- Method of producing an immunogenic composition16 Apr 2024US 11,957,746 B2
- Recombinant measles virus expressing zika virus prM and E proteins2 Jan 2024US 11,857,616 B2Centre National De La Recherche Scientifique
- Universal influenza vaccine3 Oct 2023US 11,771,756 B2Cambridge Technologies, Inc.
- Method of producing an immunogenic composition30 Jul 2026US 2026/0216312 A1Boehringer Ingelheim Animal Health USA Inc.
- Compositions and methods for making and using stabilized enveloped viruses by spray-drying and lyophilization2 Apr 2026US 2026/0091106 A1The Regents of the University of Colorado, a body corporate
- Cytolytic t cell immunotherapy for highly pathogenic coronaviruses4 Sep 2025US 2025/0276056 A1
- Viral delivery of neoantigens28 Aug 2025US 2025/0270589 A1Seattle Project Corp.
- Method of producing an immunogenic composition24 Oct 2024US 2024/0350612 A1Boehringer Ingelheim Animal Health USA Inc.
Most cited
By later US patents
- Viral vaccine composition, process and methods of use4US 7,838,006 B2Immunitor USA Inc. · 2010
- Universal influenza vaccine2US 11,351,241 B2Cambridge Technologies, Inc. · 2022
- Universal influenza vaccine1US 11,771,756 B2Cambridge Technologies, Inc. · 2023
- Method of producing an immunogenic composition1US 11,957,746 B22024
- Baculovirus system for expressing proteins forming virus-like particles1US 9,879,280 B2Alternative Gene Expression S.L. · 2018